Search
for
Did you mean TYK2 Inhibitor?
Research 10 of 229
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- A review of Janus kinase inhibitor use in scarring alopecia
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Janus Kinase inhibitors in dermatology: a review
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →